英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
playwriters查看　playwriters　在百度字典中的解释百度英翻中〔查看〕
playwriters查看　playwriters　在Google字典中的解释Google英翻中〔查看〕
playwriters查看　playwriters　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Amgen looks for Five Prime payback | ApexOnco - Clinical Trials news . . .
    One of the main reasons why Amgen paid $1 9bn for Five Prime Therapeutics in March 2021 was the anti-FGFR2b MAb bemarituzumab Four years on, with bema set to deliver its first pivotal results imminently, the company will find out whether its investment was worth it
  • NCT05325866: An ongoing trial by Amgen - TrialsTracker
    A Phase 1b 2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301) Results Status Ongoing ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial" Start date Sept 23, 2022
  • Five Prime eyes financing after positive results with stomach cancer . . .
    The FIGHT results raise the possibility that bemarituzumab – an antibody which targets fibroblast growth factor receptor 2b (FGFR2b) – could become the first new drug for previously-untreated
  • Bemarituzumab by Amgen for Adenocarcinoma Of The Gastroesophageal . . .
    Bemarituzumab [FPA-144] is under development for the treatment of solid tumors such as gastric cancer, gastroesophageal cancer, transitional cell carcinoma, lymphoma, bladder cancer, head and neck squamous cell carcinoma, lung adenocarcinoma, fallopian tube cancer, peritoneal cancer, esophageal squamous cell carcinoma, triple-negative breast
  • Bemarituzumab - Drug Targets, Indications, Patents - Synapse
    Bemarituzumab, a monoclonal antibody specific to the splice-variant FGFR2b, has shown promising results in combination with chemotherapy in phase 2 trials
  • Bemarituzumab as first-line treatment for locally advanced or . . .
    Bemarituzumab is a first-in-class, humanized monoclonal antibody specific to human FGFR2b that blocks FGF binding to the receptor Bemarituzumab acts through a two-pronged approach First, it selectively inhibits FGFR2b signaling with downstream effects on cancer cell proliferation [14, 15]
  • Amgens Investigational Targeted Treatment Bemarituzumab Granted . . .
    Bemarituzumab (anti-FGFR2b) is a potential first-in-class investigational targeted antibody that is designed to block fibroblast growth factors (FGFs) from binding and activating FGFR2b, inhibiting several downstream pro-tumor signaling pathways and potentially slowing cancer progression
  • Bemarituzumab Drug Profile - Ozmosi
    Latest Update Note: Clinical Trial Update Product Description Bemarituzumab is currently being evaluated in combination with chemotherapy in a phase III trial as front-line therapy for patients with high FGFR2b-overexpressing advanced-stage GEA
  • Bemarituzumab by Amgen for Lymphoma: Likelihood of Approval
    Bemarituzumab is under clinical development by Amgen and currently in Phase I for Lymphoma According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II
  • SINO BIOPHARM has received approval for its second indication for . . .
    Hong Kong stock leader in the pharmaceutical industry, SINO BIOPHARM, announced that the company's Class 1 innovative drug Bemarituzumab injection combined with Anlotinib hydrochloride capsules for a new indication has been approved for marketing by the National Medical Products Administration





中文字典-英文字典  2005-2009